For example, Wouters et al. [68] demonstrated that pharmacologic LXRα activation, although it doubles hepatic steatosis, reverses hepatic inflammation in parallel with reversing hepatic cholesterol levels in a high-fat, high-cholesterol-induced NASH mouse model. Here, NR1H3 is linked to metabolic dysfunction-associated steatohepatitis.